Promising Schizophrenia Drug, Cobenfy, Will Likely Face Access Challenges
Insurer access challenges likely lie ahead for the novel schizophrenia drug Cobenfy, given its considerably higher price than ...
FDA approves Cobenfy for adults with schizophrenia
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
Bristol's New Schizophrenia Drug Cobenfy Helps Support Its Wide Moat
More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...
The Associated Press on MSN19d
A promising schizophrenia drug showed mixed results. What does that mean for patients?
The Food and Drug Administration approved Cobenfy on the strength of two encouraging company-sponsored five-week trials and ...
The Hindu27d
FDA approval for Cobenfy casts light on schizophrenia’s wickedness
On September 26, the U.S. Food and Drug Administration (FDA) approved a drug called Cobenfy to treat schizophrenia. Cobenfy is a combination of xanomeline and trospium chloride that has a novel ...
Seeking Alpha8d
AbbVie: Emraclidine's Failure Eliminates An Important Growth Driver
Bristol-Myers Squibb's Cobenfy comes out as the major beneficiary and will extend its leadership in the muscarinic drug class ...
AbbVie's disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
AbbVie Inc.'s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., analysts said.
AbbVie under pressure as schizophrenia drug fails two trials
Shares of AbbVie (ABBV) are sliding on Monday after the company’s drug candidate for schizophrenia failed to meet the key goal in two ...
Seeking Alpha18d
Bristol Myers posts long-term Phase 3 data for schizophrenia drug Cobenfy
The 52-week EMERGENT-4 trial was designed to evaluate the long-term tolerability and efficacy of Cobenfy in 156 adults with schizophrenia who had previously received the drug as part of the ...